Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 286 to 300 of 887 results for score

  1. Magnetic resonance image-guided transcutaneous focused ultrasound for uterine fibroids (HTG277)

    Evidence-based recommendations on magnetic resonance image-guided transcutaneous focused ultrasound for uterine fibroids. This involves using magnetic resonance imaging (MRI) to locate the fibroids and direct high-intensity ultrasound energy to destroy fibroid tissue.

  2. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217)

    Evidence-based recommendations on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (Ebixa) for treating Alzheimer's disease in adults.

  3. Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis (TA254)

    Evidence-based recommendations on fingolimod (Gilenya) for highly active relapsing-remitting multiple sclerosis.

  4. Laparoscopic prostatectomy for benign prostatic obstruction (HTG176)

    Evidence-based recommendations on laparoscopic prostatectomy for benign prostatic obstruction. This involves removing the prostate through small cuts in the abdomen, using a fine telescope to see inside the body (keyhole surgery).

  5. Single-port laparoscopic nephrectomy (HTG278)

    Evidence-based recommendations on single-port laparoscopic nephrectomy. This involves removing the kidney using several small incisions (laparoscopy).

  6. Arthroscopic radiofrequency chondroplasty for discrete chondral defects of the knee (HTG340)

    Evidence-based recommendations on arthroscopic radiofrequency chondroplasty for discrete chondral defects of the knee. This involves using a radiofrequency probe to heat and smooth any defects and rough edges in the cartilage.

  7. Ultrasound‑enhanced, catheter‑directed thrombolysis for deep vein thrombosis (HTG375)

    Evidence-based recommendations on ultrasound enhanced catheter-directed thrombolysis for deep vein thrombosis. This involves using ultrasound waves and a drug to break up the clot.

  8. Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma (TA680)

    Evidence-based recommendations on lenalidomide (Revlimid) for maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma in adults.

  9. Filgotinib for treating moderate to severe rheumatoid arthritis (TA676)

    Evidence-based recommendations on filgotinib (Jyseleca) for moderate to severe rheumatoid arthritis in adults.

  10. LipiFlow thermal pulsation treatment for dry eyes caused by blocked meibomian glands (MIB29)

    NICE has developed a medtech innovation briefing (MIB) on LipiFlow thermal pulsation treatment for dry eyes caused by blocked meibomian glands

  11. Laser-assisted cerebral vascular anastomosis without temporary arterial occlusion (HTG161)

    Evidence-based recommendations on laser-assisted cerebral vascular anastomosis without temporary arterial occlusion. This involves using a special laser device to create a bypass without the need to temporarily interrupt the blood flow to the brain.

  12. Fetal vesico–amniotic shunt for lower urinary tract outflow obstruction (HTG129)

    Evidence-based recommendations on fetal vesico–amniotic shunt for lower urinary tract outflow obstruction. This involves inserting a cannula through the mother's abdominal and uterine walls into the amniotic cavity and subsequently into the bladder of the fetus.

  13. Artificial intelligence in mammography (MIB242)

    NICE has developed a medtech innovation briefing (MIB) on artificial intelligence in mammography .

  14. Filgotinib for treating moderately to severely active ulcerative colitis (TA792)

    Evidence-based recommendations on filgotinib (Jyseleca) for moderately to severely active ulcerative colitis in adults when conventional or biological treatment cannot be tolerated, or the disease has responded inadequately or lost response to treatment.

  15. Antimicrobial prescribing: delafloxacin for community-acquired pneumonia (ES37)

    Summary of the evidence on delafloxacin for community-acquired pneumonia in adults